GENEVA, Aug. 4 -- NANJING INNOCARE PHARMA TECH CO., LTD. (Building 8 568 Longmian Avenue, Jiangning DistrictNanjing, Jiangsu 211100), 南京天印健华医药科技有限公司 (中国江苏省南京市江宁区龙眠大道568号8号楼) filed a patent application (PCT/CN2025/071189) for "HETEROCYCLIC COMPOUND AS RIPK1 INHIBITOR" on Jan 08, 2025. With publication no. WO/2025/157004, the details related to the patent application was published on Jul 31, 2025.
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by ...